Back to News
Market Impact: 0.5

Warren Buffett Detailed Fundamental Analysis

LRCXNDAQ
Company FundamentalsAnalyst InsightsTechnology & InnovationCorporate Earnings
Warren Buffett Detailed Fundamental Analysis

Validea's guru fundamental report indicates that LAM RESEARCH CORP (LRCX) receives a 100% rating based on their Patient Investor model, which is based on the published strategy of Warren Buffett. The strategy favors firms with predictable profitability, low debt, and reasonable valuations, all of which LRCX passes according to the model's criteria. The analysis suggests strong interest in the stock based on the firm’s underlying fundamentals and valuation.

Analysis

Lam Research Corp (LRCX) has garnered a perfect 100% rating from Validea's Patient Investor model, which is structured on Warren Buffett's investment tenets emphasizing long-term, predictable profitability, low debt, and reasonable valuations. This top-tier score, significantly above the 90% threshold indicating strong interest, reflects LRCX's successful fulfillment of all criteria within this specific strategy, encompassing earnings predictability, debt service, return on equity, return on total capital, free cash flow, use of retained earnings, share repurchase, initial rate of return, and expected return. As a large-cap growth stock in the Semiconductors industry, this comprehensive endorsement based on underlying fundamentals and valuation, coupled with an 'extremely positive' sentiment score of 0.9 for LRCX, highlights a strong quantitative assessment of the company's financial health and investment appeal according to this particular model.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

extremely positive

Sentiment Score

0.90

Ticker Sentiment

LRCX0.90
NDAQ0.00

Key Decisions for Investors

  • Investors adhering to a long-term, value-oriented strategy similar to Warren Buffett's may consider LRCX for further investigation, given its exceptional 100% rating on the Patient Investor model.
  • The company's success in meeting all fundamental criteria, including profitability, low debt, and capital efficiency metrics, suggests a robust financial profile that could warrant inclusion in diversified portfolios.
  • Given LRCX operates in the dynamic semiconductor industry, investors should complement this model-based positive assessment with an analysis of prevailing sector trends and company-specific catalysts before committing capital.